Abstract:BACKGROUND:Benazepril hydrochloride is an angiotensin-converting enzyme inhibitor. Previous clinical trials show that antihypertensive treatment with benazepril provides effective blood pressure (BP) control and is generally well tolerated by patients with hypertension. However, the long-term antihypertensive effects and tolerability of benazepril remain to be established in Chinese patients with hypertension. OBJECTIVE:The aim of this study was to investigate the long-term efficacy and tolerability of benazepril in Chinese patients with essential hypertension. METHODS:This 36-month, community-based, open-label, postmarketing surveillance study was conducted in the Nanshi District (Shanghai, China). Chinese patients with essential hypertension were to receive 1 or more benazepril tablets PO QD in the morning for 36 months. Data for BP and pulse pressure (PP) were collected at baseline (month 0) and throughout the surveillance period. The rate of patients achieving BP targets (systolic BP [SBP]/diastolic BP [DBP], <140/<90 mm Hg) was determined, as was the rate of decrease in BP. Subanalyses by sex and age group also were conducted. RESULTS:A total of 1831 patients (1090 men, 741 women; mean [SD] age, 55.8 [10.1] years [range, 35-88 years]) entered the study. After the 36-month treatment period, 75.7% of patients receiving benazepril as prescribed (1289 patients) had achieved the SBP target, 87.4% achieved the DBP target, and 71.5% achieved both targets. After 36 months of treatment, the mean (SD) decreases in SBP, DBP, and PP were 15.1 (0.4) mm Hg, 11.0 (0.3) mm Hg, and 4.2 (0.4) mm Hg, respectively, among compliers. In general, the rate of BP decrease slowed over time. No serious adverse drug reactions (ADRs) were detected during the 36-month follow-up period. All ADRs except cough (19.9%) occurred at a relatively low incidence rate (<3.0%). The cumulative incidence of benazepril related cough was statistically significantly higher in women than in men (23.6% vs 18.8%, respectively; P = 0.007). Of the 1831 patients studied, 1360 patients (74.3%) persisted in taking benazepril and were considered optimally compliant at 36-month follow-up. CONCLUSION:In this study of Chinese patients with hypertension, benazepril was associated with prolonged, stable efficacy in lowering BP and relatively low incidence of ADRs.

A Multicentre Study of the Safety of Ramiprill in High-Risk Cardiovascular Patients

Studies on Bioequivalence of Ramipril Capsule in Healthy Volunteers

High-Performance Liquid Chromatography-Mass Spectrometric Analysis of Ramipril and Its Active Metabolite Ramiprilat in Human Serum: Application to A Pharmacokinetic Study in the Chinese Volunteers

Occurrence of composite cardiac endpoints with change in resting heart rate among Chinese patients with coronary artery disease: Chinese cohort from the real-world BISO-CAD study.

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

E0352 Efficacy and Safety of Aliskiren in Chinese Patients with Mild or Moderate Essential Hypertension

Evaluation of Metoprolol Standard Dosing Pathway in Chinese Patients with Acute Coronary Syndrome: a Prospective Multicenter Single-Arm Interventional Study

Heart Rate Control is Associated with Reduced Cardiovascular Events in Asian Patients with Coronary Artery Disease Treated with Bisoprolol (BISO-CAD): Results from a Multi-National, Real-World Experience

COMPREHENSIVE ASSESSMENT OF CLINICAL EVIDENCE OF RAMIPRIL--AN EXPLORATION OF EVIDENCE BASED DRUG ASSESSMENT

Efficacy and Safety of Aliskiren, a Direct Renin Inhibitor, Compared with Ramipril in Asian Patients with Mild to Moderate Hypertension

EFFICACY AND SAFETY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYSTEM VERSUS RAMIPRIL IN CHINESE AND EUROPEAN PATIENTS WITH HYPERTENSION.

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Randomised Trial of Ramipril in Repaired Tetralogy of Fallot and Pulmonary Regurgitation

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

Pharmacokinetics of Ramipril Capsules in Healthy Volunteers

Pharmacokinetics and bioequivalence of domestic and imported ramipril tablets

Postmarketing surveillance study of benazepril in chinese patients with hypertension: An open-label, experimental, epidemiologic study

Efficacy and Safety of Rosuvastatin Versus Atorvastatin in High-Risk Chinese Patients with Hypercholesterolemia: a Randomized, Double-Blind, Active-Controlled Study

Short report: Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design

G-002 AMLODIPINE/VALSARTAN 5/160 MG VERSUS VALSARTAN 160 MG IN PREDOMINANTLY CHINESE PATIENTS WITH STAGE 1 OR 2 ESSENTIAL HYPERTENSION NOT ADEQUATELY CONTROLLED ON VALSARTAN 160 MG MONOTHERAPY

Study comparatively levamlodipine and ramipril on treating essential hypertension